Ibrutinib for the treatment of Mantle Cell Lymphoma (MCL)- evaluating the correlation between patient-reported outcomes and durability of response in a Phase 2 study
Abstract
Authors
S. Rule A. Goy P. Martin R. Ramchandren J. Alexeeva R. Popat I. Avivi R. Advani S. Le Gouill N. Horowitz Z. Yuan B. Kranenburg S.H. Zhuang W. Deraedt A. Rizo M. Wildgust M. Wang